<?xml version="1.0" encoding="UTF-8"?>
<!-- This sitemap was dynamically generated on November 14, 2026 at 1:58 PM by All in One SEO v5.0.5.1 - the original SEO plugin for WordPress. -->

<?xml-stylesheet type="text/xsl" href="https://cgxpwire.com/default-sitemap.xsl"?>

<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
	<channel>
		<title>cGxP.wire</title>
		<link><![CDATA[https://cgxpwire.com]]></link>
		<description><![CDATA[cGxP.wire]]></description>
		<lastBuildDate><![CDATA[Sat, 14 Nov 2026 07:25:52 +0000]]></lastBuildDate>
		<docs>https://validator.w3.org/feed/docs/rss2.html</docs>
		<atom:link href="https://cgxpwire.com/sitemap.rss" rel="self" type="application/rss+xml" />
		<ttl><![CDATA[60]]></ttl>

		<item>
			<guid><![CDATA[https://cgxpwire.com/eisai-and-biogen-launch-leqembi-pen-in-japan/]]></guid>
			<link><![CDATA[https://cgxpwire.com/eisai-and-biogen-launch-leqembi-pen-in-japan/]]></link>
			<title>Eisai and Biogen Launch LEQEMBI Pen in Japan</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 07:25:52 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/bracco-and-avicenna-ai-win-fda-clearance-for-aneurysm-ai/]]></guid>
			<link><![CDATA[https://cgxpwire.com/bracco-and-avicenna-ai-win-fda-clearance-for-aneurysm-ai/]]></link>
			<title>Bracco and Avicenna.AI Win FDA Clearance for Aneurysm AI</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 06:16:20 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/daiichi-sankyo-seeks-japan-approval-for-enhertu-in-uterine-cancer/]]></guid>
			<link><![CDATA[https://cgxpwire.com/daiichi-sankyo-seeks-japan-approval-for-enhertu-in-uterine-cancer/]]></link>
			<title>Daiichi Sankyo Seeks Japan Approval for Enhertu in Uterine Cancer</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 06:10:11 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/regeneron-reports-phase-2-baloncibart-results-in-pots/]]></guid>
			<link><![CDATA[https://cgxpwire.com/regeneron-reports-phase-2-baloncibart-results-in-pots/]]></link>
			<title>Regeneron Reports Phase 2 Baloncibart Results in POTS</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 05:56:56 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/virtuoso-surgical-wins-fda-nod-for-robotic-bladder-system/]]></guid>
			<link><![CDATA[https://cgxpwire.com/virtuoso-surgical-wins-fda-nod-for-robotic-bladder-system/]]></link>
			<title>Virtuoso Surgical Wins FDA Nod for Robotic Bladder System</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 05:52:22 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/kazia-therapeutics-to-showcase-novel-nuclear-pd-l1-degrader/]]></guid>
			<link><![CDATA[https://cgxpwire.com/kazia-therapeutics-to-showcase-novel-nuclear-pd-l1-degrader/]]></link>
			<title>Kazia Therapeutics to Showcase Novel Nuclear PD-L1 Degrader</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 05:47:31 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/imvionix-acquires-beovu-commercial-rights-from-novartis/]]></guid>
			<link><![CDATA[https://cgxpwire.com/imvionix-acquires-beovu-commercial-rights-from-novartis/]]></link>
			<title>IMVIONIX Acquires BEOVU® Commercial Rights from Novartis</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 05:43:14 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/bechtel-medical-wins-fda-clearance-for-wound-vox-system/]]></guid>
			<link><![CDATA[https://cgxpwire.com/bechtel-medical-wins-fda-clearance-for-wound-vox-system/]]></link>
			<title>Bechtel Medical Wins FDA Clearance for Wound VOX System</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 05:30:54 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/abbisko-wins-u-s-fda-approval-for-pimicotinib-in-tgct/]]></guid>
			<link><![CDATA[https://cgxpwire.com/abbisko-wins-u-s-fda-approval-for-pimicotinib-in-tgct/]]></link>
			<title>Abbisko Wins U.S. FDA Approval for Pimicotinib in TGCT</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 05:25:31 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/c2n-partners-with-lsi-medience-for-alzheimers-test/]]></guid>
			<link><![CDATA[https://cgxpwire.com/c2n-partners-with-lsi-medience-for-alzheimers-test/]]></link>
			<title>C2N Partners With LSI Medience for Alzheimer’s Test</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 04:58:50 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/helix-launches-clinicogenomic-research-access-program/]]></guid>
			<link><![CDATA[https://cgxpwire.com/helix-launches-clinicogenomic-research-access-program/]]></link>
			<title>Helix Launches Clinicogenomic Research Access Program</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 04:57:50 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/arga-medtech-completes-key-atrial-fibrillation-trial-milestone/]]></guid>
			<link><![CDATA[https://cgxpwire.com/arga-medtech-completes-key-atrial-fibrillation-trial-milestone/]]></link>
			<title>Argá Medtech Completes Key Atrial Fibrillation Trial Milestone</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 04:50:11 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/lupin-launches-ranluspec-biosimilar-across-european-markets/]]></guid>
			<link><![CDATA[https://cgxpwire.com/lupin-launches-ranluspec-biosimilar-across-european-markets/]]></link>
			<title>Lupin Launches Ranluspec Biosimilar Across European Markets!</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 04:05:31 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/teva-targets-6-7b-innovative-medicines-revenue-by-2030/]]></guid>
			<link><![CDATA[https://cgxpwire.com/teva-targets-6-7b-innovative-medicines-revenue-by-2030/]]></link>
			<title>Teva Targets $6–7B Innovative Medicines Revenue by 2030</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 03:52:34 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/alzheon-advances-phase-3-oral-alzheimers-drug-development/]]></guid>
			<link><![CDATA[https://cgxpwire.com/alzheon-advances-phase-3-oral-alzheimers-drug-development/]]></link>
			<title>Alzheon Advances Phase 3 Oral Alzheimer&#8217;s Drug Development</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 03:48:16 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/laekna-showcases-novel-oral-obesity-candidate-lae124/]]></guid>
			<link><![CDATA[https://cgxpwire.com/laekna-showcases-novel-oral-obesity-candidate-lae124/]]></link>
			<title>Laekna Showcases Novel Oral Obesity Candidate LAE124</title>
			<pubDate><![CDATA[Fri, 13 Nov 2026 05:24:01 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/caristo-ai-score-improves-heart-risk-prediction-in-19110/]]></guid>
			<link><![CDATA[https://cgxpwire.com/caristo-ai-score-improves-heart-risk-prediction-in-19110/]]></link>
			<title>Caristo AI Score Improves Heart Risk Prediction in 19,110</title>
			<pubDate><![CDATA[Fri, 13 Nov 2026 05:20:48 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/antengene-presents-atg-207-preclinical-data-at-acr-2026/]]></guid>
			<link><![CDATA[https://cgxpwire.com/antengene-presents-atg-207-preclinical-data-at-acr-2026/]]></link>
			<title>Antengene Presents ATG-207 Preclinical Data at ACR 2026</title>
			<pubDate><![CDATA[Fri, 13 Nov 2026 05:19:24 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/skribe-advances-wearable-heart-monitoring-for-cancer-patients/]]></guid>
			<link><![CDATA[https://cgxpwire.com/skribe-advances-wearable-heart-monitoring-for-cancer-patients/]]></link>
			<title>Skribe Advances Wearable Heart Monitoring for Cancer Patients</title>
			<pubDate><![CDATA[Fri, 13 Nov 2026 05:11:38 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/lupus-research-alliance-awards-prize-for-tlr7-discovery/]]></guid>
			<link><![CDATA[https://cgxpwire.com/lupus-research-alliance-awards-prize-for-tlr7-discovery/]]></link>
			<title>Lupus Research Alliance Awards Prize for TLR7 Discovery</title>
			<pubDate><![CDATA[Fri, 13 Nov 2026 05:02:58 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/shanton-pharma-wins-fda-and-ema-waivers-for-sap-001/]]></guid>
			<link><![CDATA[https://cgxpwire.com/shanton-pharma-wins-fda-and-ema-waivers-for-sap-001/]]></link>
			<title>Shanton Pharma Wins FDA and EMA Waivers for SAP-001</title>
			<pubDate><![CDATA[Fri, 13 Nov 2026 04:51:33 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/abbott-wins-fda-approval-for-ultisynq-heart-device-lead/]]></guid>
			<link><![CDATA[https://cgxpwire.com/abbott-wins-fda-approval-for-ultisynq-heart-device-lead/]]></link>
			<title>Abbott Wins FDA Approval for UltiSynq Heart Device Lead</title>
			<pubDate><![CDATA[Fri, 13 Nov 2026 04:45:58 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/metagenomi-gains-fda-ind-clearance-for-hemophilia-a/]]></guid>
			<link><![CDATA[https://cgxpwire.com/metagenomi-gains-fda-ind-clearance-for-hemophilia-a/]]></link>
			<title>Metagenomi Gains FDA IND Clearance for Hemophilia A</title>
			<pubDate><![CDATA[Fri, 13 Nov 2026 04:40:40 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/beeline-reports-positive-phase-2-results-for-afimetoran/]]></guid>
			<link><![CDATA[https://cgxpwire.com/beeline-reports-positive-phase-2-results-for-afimetoran/]]></link>
			<title>Beeline Reports Positive Phase 2 Results for Afimetoran</title>
			<pubDate><![CDATA[Fri, 13 Nov 2026 04:33:05 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/nimbus-starts-phase-1-trial-of-oral-sik2-inhibitor-drug/]]></guid>
			<link><![CDATA[https://cgxpwire.com/nimbus-starts-phase-1-trial-of-oral-sik2-inhibitor-drug/]]></link>
			<title>Nimbus Starts Phase 1 Trial of Oral SIK2 Inhibitor Drug</title>
			<pubDate><![CDATA[Fri, 13 Nov 2026 04:28:32 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/pfizer-secures-1-5b-blackstone-funding-for-obesity-drug/]]></guid>
			<link><![CDATA[https://cgxpwire.com/pfizer-secures-1-5b-blackstone-funding-for-obesity-drug/]]></link>
			<title>Pfizer Secures $1.5B Blackstone Funding for Obesity Drug</title>
			<pubDate><![CDATA[Fri, 13 Nov 2026 04:19:28 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/cu-anschutz-publishes-roadmap-for-pediatric-diabetes-immunotherapy/]]></guid>
			<link><![CDATA[https://cgxpwire.com/cu-anschutz-publishes-roadmap-for-pediatric-diabetes-immunotherapy/]]></link>
			<title>CU Anschutz Publishes Roadmap for Pediatric Diabetes Immunotherapy</title>
			<pubDate><![CDATA[Fri, 13 Nov 2026 04:12:21 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/ascletis-submits-oral-obesity-drug-combination-to-fda/]]></guid>
			<link><![CDATA[https://cgxpwire.com/ascletis-submits-oral-obesity-drug-combination-to-fda/]]></link>
			<title>Ascletis Submits Oral Obesity Drug Combination to FDA</title>
			<pubDate><![CDATA[Fri, 13 Nov 2026 04:09:02 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/ai4eyes-completes-fda-registration-for-ai-eye-care-platform/]]></guid>
			<link><![CDATA[https://cgxpwire.com/ai4eyes-completes-fda-registration-for-ai-eye-care-platform/]]></link>
			<title>AI4Eyes Completes FDA Registration for AI Eye Care Platform</title>
			<pubDate><![CDATA[Fri, 13 Nov 2026 04:04:28 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/amgen-reports-positive-phase-3-dazodalibep-results-sjogren/]]></guid>
			<link><![CDATA[https://cgxpwire.com/amgen-reports-positive-phase-3-dazodalibep-results-sjogren/]]></link>
			<title>Amgen Reports Positive Phase 3 Dazodalibep Results: Sjögren</title>
			<pubDate><![CDATA[Fri, 13 Nov 2026 03:57:03 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/lilly-reports-one-year-results-for-taltz-and-zepbound/]]></guid>
			<link><![CDATA[https://cgxpwire.com/lilly-reports-one-year-results-for-taltz-and-zepbound/]]></link>
			<title>Lilly Reports One-Year Results for Taltz and Zepbound</title>
			<pubDate><![CDATA[Thu, 12 Nov 2026 04:31:13 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/waters-wins-fda-clearance-for-leukemia-flow-cytometry-tests/]]></guid>
			<link><![CDATA[https://cgxpwire.com/waters-wins-fda-clearance-for-leukemia-flow-cytometry-tests/]]></link>
			<title>Waters Wins FDA Clearance for Leukemia Flow Cytometry Tests</title>
			<pubDate><![CDATA[Thu, 12 Nov 2026 04:26:26 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/lipocine-starts-phase-3-bloom-trial-for-postpartum-depression/]]></guid>
			<link><![CDATA[https://cgxpwire.com/lipocine-starts-phase-3-bloom-trial-for-postpartum-depression/]]></link>
			<title>Lipocine Starts Phase 3 BLOOM Trial for Postpartum Depression</title>
			<pubDate><![CDATA[Thu, 12 Nov 2026 04:18:32 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/adcendo-to-present-adce-d01-phase-1-sarcoma-data/]]></guid>
			<link><![CDATA[https://cgxpwire.com/adcendo-to-present-adce-d01-phase-1-sarcoma-data/]]></link>
			<title>Adcendo to Present ADCE-D01 Phase 1 Sarcoma Data</title>
			<pubDate><![CDATA[Thu, 12 Nov 2026 04:13:07 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/azitra-reports-atr-cosf-results-for-wrinkle-reduction/]]></guid>
			<link><![CDATA[https://cgxpwire.com/azitra-reports-atr-cosf-results-for-wrinkle-reduction/]]></link>
			<title>Azitra Reports ATR-COSF Results for Wrinkle Reduction</title>
			<pubDate><![CDATA[Thu, 12 Nov 2026 04:09:38 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/francis-medical-secures-jj-funding-to-expand-vanquish/]]></guid>
			<link><![CDATA[https://cgxpwire.com/francis-medical-secures-jj-funding-to-expand-vanquish/]]></link>
			<title>Francis Medical Secures J&amp;J Funding to Expand Vanquish</title>
			<pubDate><![CDATA[Thu, 12 Nov 2026 04:06:09 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/ambrosia-presents-two-oral-obesity-drug-candidates-in-2026/]]></guid>
			<link><![CDATA[https://cgxpwire.com/ambrosia-presents-two-oral-obesity-drug-candidates-in-2026/]]></link>
			<title>Ambrosia Presents Two Oral Obesity Drug Candidates in 2026</title>
			<pubDate><![CDATA[Thu, 12 Nov 2026 04:02:14 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/layer-health-wins-2026-accenture-healthtech-innovation-award/]]></guid>
			<link><![CDATA[https://cgxpwire.com/layer-health-wins-2026-accenture-healthtech-innovation-award/]]></link>
			<title>Layer Health Wins 2026 Accenture HealthTech Innovation Award</title>
			<pubDate><![CDATA[Thu, 12 Nov 2026 04:01:39 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/10x-genomics-launches-500-patient-breast-cancer-study/]]></guid>
			<link><![CDATA[https://cgxpwire.com/10x-genomics-launches-500-patient-breast-cancer-study/]]></link>
			<title>10x Genomics Launches 500-Patient Breast Cancer Study</title>
			<pubDate><![CDATA[Thu, 12 Nov 2026 03:58:32 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/jubilant-therapeutics-reports-promising-jbi-802-clinical-data/]]></guid>
			<link><![CDATA[https://cgxpwire.com/jubilant-therapeutics-reports-promising-jbi-802-clinical-data/]]></link>
			<title>Jubilant Therapeutics Reports Promising JBI-802 Clinical Data</title>
			<pubDate><![CDATA[Thu, 12 Nov 2026 03:43:37 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/novo-nordisk-commits-200m-to-global-diabetes-care-programs/]]></guid>
			<link><![CDATA[https://cgxpwire.com/novo-nordisk-commits-200m-to-global-diabetes-care-programs/]]></link>
			<title>Novo Nordisk Commits $200M to Global Diabetes Care Programs</title>
			<pubDate><![CDATA[Thu, 12 Nov 2026 03:37:04 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/moderna-reports-mnexspike-covid-19-vaccine-study-results/]]></guid>
			<link><![CDATA[https://cgxpwire.com/moderna-reports-mnexspike-covid-19-vaccine-study-results/]]></link>
			<title>Moderna Reports mNEXSPIKE COVID-19 Vaccine Study Results</title>
			<pubDate><![CDATA[Thu, 12 Nov 2026 03:32:18 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/iaso-bio-wins-china-ind-approval-for-iaso208-car-t/]]></guid>
			<link><![CDATA[https://cgxpwire.com/iaso-bio-wins-china-ind-approval-for-iaso208-car-t/]]></link>
			<title>IASO Bio Wins China IND Approval for IASO208 CAR-T</title>
			<pubDate><![CDATA[Thu, 12 Nov 2026 03:31:36 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/cu-anschutz-study-reveals-maternal-effects-in-type-1-diabetes/]]></guid>
			<link><![CDATA[https://cgxpwire.com/cu-anschutz-study-reveals-maternal-effects-in-type-1-diabetes/]]></link>
			<title>CU Anschutz Study Reveals Maternal Effects in Type 1 Diabetes</title>
			<pubDate><![CDATA[Thu, 12 Nov 2026 03:28:44 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/eli-lilly-highlights-foundayo-in-new-weight-health-campaigns/]]></guid>
			<link><![CDATA[https://cgxpwire.com/eli-lilly-highlights-foundayo-in-new-weight-health-campaigns/]]></link>
			<title>Eli Lilly Highlights Foundayo in New Weight-Health Campaigns</title>
			<pubDate><![CDATA[Thu, 12 Nov 2026 03:28:06 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/cepheid-gains-ivdr-ce-mark-for-respiratory-panel/]]></guid>
			<link><![CDATA[https://cgxpwire.com/cepheid-gains-ivdr-ce-mark-for-respiratory-panel/]]></link>
			<title>Cepheid Gains IVDR CE Mark for Respiratory Panel</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 04:32:56 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/curia-expands-precision-fermentation-capacity-in-spain/]]></guid>
			<link><![CDATA[https://cgxpwire.com/curia-expands-precision-fermentation-capacity-in-spain/]]></link>
			<title>Curia Expands Precision Fermentation Capacity in Spain</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 04:29:49 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/boehringers-scovella-gains-positive-eu-opinion/]]></guid>
			<link><![CDATA[https://cgxpwire.com/boehringers-scovella-gains-positive-eu-opinion/]]></link>
			<title>Boehringer’s SCOVELLA Gains Positive EU Opinion</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 04:26:14 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/alnylam-reports-five-year-amvuttra-benefits-in-attr-cm/]]></guid>
			<link><![CDATA[https://cgxpwire.com/alnylam-reports-five-year-amvuttra-benefits-in-attr-cm/]]></link>
			<title>Alnylam Reports Five-Year AMVUTTRA Benefits in ATTR-CM</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 04:22:28 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/eilean-reports-first-human-malt1-degradation/]]></guid>
			<link><![CDATA[https://cgxpwire.com/eilean-reports-first-human-malt1-degradation/]]></link>
			<title>Eilean Reports First Human MALT1 Degradation</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 04:19:36 +0000]]></pubDate>
		</item>
				</channel>
</rss>
